e-ISSN 2147-2475

Hzl Arama




Laparoscopic Endoscopic Surgical Science diopatik Pulmoner Hipertansiyonlu Bir Hastada Oral Selexipagden Subkutan Treprostinile Gei: Sekiz Gnlk Bir Protokol [Respir Case Rep]
Respir Case Rep. 2022; 11(1): 30-35 | DOI: 10.5505/respircase.2022.55476

diopatik Pulmoner Hipertansiyonlu Bir Hastada Oral Selexipagden Subkutan Treprostinile Gei: Sekiz Gnlk Bir Protokol

Wan-jing Ho, Chia-pin Lin, Lung-An Hsu, Chun-li Wang
Chang Gung Universitesi, Tp Fakltesi, Chan Gung Memorial Hastanesi, Kardiyoloji Servisi, Taoyuan, Tayvan

Pulmoner arteriyel hipertansiyon (PAH) ilerleyici ve gten drc bir hastalktr. Spesifik ilalar, nitrik oksit, endotelin ve prostasiklin yollarn hedeflemektedir. Oral ilalar genellikle dk riskli hastalarda uygulanrken, yksek riskli hastalarda, zellikle WHO fonksiyonel snf IV olanlarda veya oral ilalarn teraptik hedeflerine ulaamayanlarda, parenteral prostanoidler nerilmektedir. Selexipag, selektif bir prostasiklin (PGI2) reseptr agonistidir. Treprostinil bir prostasiklin analoudur. Oral seleksipagdan subkutan (SC) treprostinile gei iin standart bir klavuz yoktur. diyopatik PAH'l bir hastada bu geie baarl bir yaklam tanmladk. Klinik uygulamada faydal bir rehber olabilecek 8 gnlk bir protokol sunuyoruz. Oral seleksipag'n SC treprostinile tahmini edeer dozlar gnde iki kez 200 g = 5 ng/kg/dk'dr. Geiten sonra semptomlarda, serum B tipi natriretik peptit seviyelerinde, oksijen satrasyonunda ve ekokardiyografik parametrelerde iyilemeler oldu.

Anahtar Kelimeler: Ppulmoner arterial hipertansiyon, selexipag, treprostinil

Transition from Oral Selexipag to Subcutaneous Treprostinil in a Patient with Idiopathic Pulmonary Arterial Hypertension: An Eight-Day Protocol

Wan-jing Ho, Chia-pin Lin, Lung-An Hsu, Chun-li Wang
Department of Cardiology, Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Taoyuan, Taiwan

Pulmonary arterial hypertension (PAH) is a progressive and debilitating disorder. Specific medications target the nitric oxide, endothelin and prostacyclin pathways. Oral medications are usually administered in low-risk patients, while parenteral prostanoids are recommended for those at high risk, especially those with a WHO functional class of IV or those in whom the therapeutic goals of oral medications were not achieved. Selexipag is a selective prostacyclin (PGI2) receptor (IP receptor) agonist, while Treprostinil is a prostacyclin analog. There are no standard guidelines directing the transition from oral selexipag to subcutaneous (SC) treprostinil. We describe here a successful approach to this transition in a patient with idiopathic PAH, proposing an 8-day protocol that may serve as a useful guide in clinical practice. The estimated equivalent doses of oral selexipag to SC treprostinil is 200 g twice daily = 5 ng/kg/min. Following the transition, the patient experienced improvements in symptoms, serum B-type natriuretic peptide levels, oxygen saturation and echocardiographic parameters.

Keywords: Pulmonary arterial hypertension, selexipag, treprostinil

Wan-jing Ho, Chia-pin Lin, Lung-An Hsu, Chun-li Wang. Transition from Oral Selexipag to Subcutaneous Treprostinil in a Patient with Idiopathic Pulmonary Arterial Hypertension: An Eight-Day Protocol. Respir Case Rep. 2022; 11(1): 30-35

Sorumlu Yazar: Wan-jing Ho, Taiwan
Makale Dili: ngilizce
LookUs & Online Makale